New frontiers in the medical management of gastrointestinal stromal tumours

The tyrosine kinase inhibitor (TKI) imatinib has radically changed the natural history of KIT-driven gastrointestinal stromal tumours (GISTs). Approved second-line and third-line medical therapies are represented by the TKIs sunitinib and regorafenib, respectively. While imatinib remains the cardina...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazzocca, Alessandro, Napolitano, Andrea, Silletta, Marianna, Spalato Ceruso, Mariella, Santini, Daniele, Tonini, Giuseppe, Vincenzi, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535752/
https://www.ncbi.nlm.nih.gov/pubmed/31205499
http://dx.doi.org/10.1177/1758835919841946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535752/
https://www.ncbi.nlm.nih.gov/pubmed/31205499
http://dx.doi.org/10.1177/1758835919841946

Ejemplares similares